login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Cardiovascular effects of Japan’s 2011 earthquake and tsunami: Incidence rises with the seismic peak


Tuesday, 28 Aug 2012 16:24

The Japanese earthquake and tsunami of 11 March 2011, which hit the north-east coast of Japan with a magnitude of 9.0 on the Richter scale, was one of the largest ocean-trench earthquakes ever recorded in Japan. The tsunami caused huge damage, including 15,861 dead and 3018 missing persons, and, as of 6 June 2012, 388,783 destroyed homes.

Following an investigation of the ambulance records made by doctors in the Miyagi prefecture, close to the epicentre of the earthquake and where the damage was greatest, cardiologist Hiroaki Shimokawa and colleagues from the Tohoku University Graduate School of Medicine at Sendai, Japan, found that the weekly occurrence of five conditions – heart failure, acute coronary syndrome (including unstable angina and acute myocardial infarction), stroke, cardio-pulmonary arrest and pneumonia – all increased sharply soon after the earthquake occurred.

Such reactions – in acute coronary syndrome, stroke and pulmonary embolism – have been reported before, said Shimokawa, in Japan, China and the USA. However, these studies reported only the short-term occurrence of individual cardiovascular disease events, and the mid-term cardiovascular disease effects of such great earthquakes remain to be elucidated. To this end, the study examined all ambulance transport records in the Miyagi prefecture from 11 February to 30 June for each year from 2008 to 2011 (ie, four weeks before to 16 weeks after 11 March, a total of 124,152 records). Incidence records from before, during and after the earthquake disaster were compared, the aftershocks counted and recorded according to a seismic intensity of 1 or greater.

The number of aftershocks in the Miyagi prefecture was frequent during the six weeks after the earthquake, and the second peak was noted as a large aftershock on 7 April 2011 (magnitude of 7.0). Compared with the previous three years, the significant increases in the occurrence of heart failure and pneumonia were steadily prolonged for more than six weeks after the tsunami struck. On the other hand, the incident increases in stroke and cardio-pulmonary arrest followed the pattern of the first and aftershock seismic peaks. The rapid increases in the occurrence of acute coronary syndromes and cardio-pulmonary arrest was followed by a sharp and significant decline. Interestingly, said Shimokawa, age, sex or residence area did not significantly affect the occurrences of cardiovascular disease during or following the tsunami.

“To the best of our knowledge,” he added, “this is the first report to describe the mid-term course of major cardiovascular events and pneumonia after a great earthquake in a large population. In particular, our findings provide the first evidence that the incidence of heart failure was markedly increased over a long period afterwards.” Prevalence of pneumonia, a well known risk factor for deteriorating heart failure, was significantly increased.

The Tohoku University study also found - as reflected in self-monitoring measurements – that blood pressure was significantly elevated after the earthquake. However, transport disruption following the tsunami interrupted delivery of regular medications, such as antihypertensive or antithrombotic drugs, and this may have contributed to the increased cardiovascular events. There was also an increase in the occurrences of ventricular tachyarrhythmias in patients with implantable cardiac defibrillators.

“Taken together,” said Shimokawa, “we consider that discontinuation of drugs, activated sympathetic nervous system, rising blood pressure, and the increased occurrence of tachyarrhythmia and infections were all involved in the increased occurrence of cardiovascular events after the Great Earthquake of Japan.”




Add New Comment

Most popular


Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published
Wednesday, 27 Aug 2014
A new European joint consensus document on the use of antithrombotic drugs in patients with atrial fibrillation presenting with an acute coronary syndrome and undergoing percutaneous coronary ... Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published

No severe paravalvular leak with Acurate Neo TF
Monday, 29 Sep 2014
Data presented at PCR London Valves (28–30 September, London, UK) indicate that the Acurate Neo transfemoral TAVI system, which recently received the CE mark, is not associated with any incidences of ... No severe paravalvular leak with Acurate Neo TF

ABSORB II study shows Absorb is comparable to Xience drug-eluting stent
Wednesday, 17 Sep 2014
At one year, overall clinical outcomes for Absorb (Abbott) were comparable to Xience (Abbott), and people treated with Absorb experienced a significantly lower rate of angina. ABSORB II study shows Absorb is comparable to Xience drug-eluting stent

Features


The promise of chemical renal denervation
Friday, 05 Sep 2014
Tim A Fischell writes that chemical renal denervation using ethanol may have numerous advantages over energy-based “burning” technologies. The promise of chemical renal denervation

Drug-coated balloons for the management of coronary artery disease
Thursday, 04 Sep 2014
Robert Byrne writes that although drug-coated balloon therapy has been a significant innovation with relevance for everyday practice, convincing data in the coronary arena exists thus far only for ... Drug-coated balloons for the management of coronary artery disease

Profiles


Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions